The pharmacokinetics of moxalactam were investigated in five subjects with normal renal function and 21 uremic patients. Normal subjects were given intravenous doses of 7.5 subjects with normal renal function, the mean peak serum levels, occurring at 0.95 ± 0.37 h, were 48.28 ± 11.81 ,ug/ml, the t1/21 value was 2.22 ± 0.16 h, the renal clearance (CR) was 87.5 ± 9.4 ml/min per 1.73 m2, and 96.9 ± 12.7% of the injected dose was found in 24-h urine. Pharmacokinetic data were similar for the two routes of administration. In uremic patients, the t1/2# increased according to the severity of renal failure; it was 4.83 h in patients with creatinine clearances (Cc,) within 30 to 60 ml/min per 1.73 M2, 8.42 h for Cc, values within 10 to 30 ml/min, and 18.95 h in hemodialysis patients. During a 4-to 6-h dialysis session, the t1/2p value was 3.65 h and 51% of the drug was removed by dialysis. The apparent volume of distribution at steady state increased in patients with C,. values below 10 ml/min; serum and renal clearances decreased in uremic patients, and the nonrenal clearances remained constant in all these patients. From these pharmacokinetic results, linear relationships were found between the kinetic data and the biological parameters of the glomerular filtration rate. Dosage schedules were established, adapted to the degree of renal impairment.
The pharmacokinetics of moxalactam were investigated in five subjects with normal renal function and 21 uremic patients. Normal subjects were given intravenous doses of 7.5 and 15 mg of the drug per kg as bolus injections (1 min) and 30 mg of the drug per kg as a 20-min infusion. Phannacokinetic data, cakulated by using a two-compartment open body model, were similar for the three intravenous doses: the t112. value was within 0.12 to 0.20 h, the t11I value was 1.98 to 2.05 h, the central distribution volume (1V,) was 3.81 to 7.04 liters/1.73 m2, and the apparent volume of distribution at steady state (Va.) was 9.12 to 13 .36 liters/1.73 m2, i.e., 13.7 to 20.2% of the body weight. From 82.0 to 97.7% of the dose was recovered, in unchanged form, in urine during 24 h. After a single intramuscular dose of 15 mg/kg in the same subjects with normal renal function, the mean peak serum levels, occurring at 0.95 ± 0.37 h, were 48.28 ± 11.81 ,ug/ml, the t1/21 value was 2.22 ± 0.16 h, the renal clearance (CR) was 87.5 ± 9.4 ml/min per 1.73 m2, and 96.9 ± 12.7% of the injected dose was found in 24-h urine. Pharmacokinetic data were similar for the two routes of administration. In uremic patients, the t1/2# increased according to the severity of renal failure; it was 4.83 h in patients with creatinine clearances (Cc,) within 30 to 60 ml/min per 1.73 M2, 8 .42 h for Cc, values within 10 to 30 ml/min, and 18 .95 h in hemodialysis patients. During a 4-to 6-h dialysis session, the t1/2p value was 3 .65 h and 51% of the drug was removed by dialysis. The apparent volume of distribution at steady state increased in patients with C,. values below 10 ml/min; serum and renal clearances decreased in uremic patients, and the nonrenal clearances remained constant in all these patients. From these pharmacokinetic results, linear relationships were found between the kinetic data and the biological parameters of the glomerular filtration rate. Dosage schedules were established, adapted to the degree of renal impairment.
The purpose of this study was to define the pharmacokinetic properties of moxalactam, a semisynthetic 1-oxa-,B-lactam, in subjects with normal renal function and in patients with various degrees of renal impairment.
MATERIALS AND METHODS
Subjects studied. Twenty-six subjects, with no known sensitivity to penicillins or cephalosporins, were selected for this study. AU (6, 8) . Standards were prepared in pooled human serum for serum analyses and in phosphate buffer (pH 6) for urine analyses. All assays were performed in triplicate. For all concentrations in the measured range (0.78 to 25 ug/ml), the 95% confidence limits did not exceed 6% of the determined values.
Creatinine measurements. The creatinine concentrations in serum and urine were measured by the colorimetric method of Jaffe (4 (Fig. 1) . Moxalactam is excreted mainly through the kidneys, since 82.0 to 96.9% of the dose was recovered in unchanged forn in 24-h urine samples. Renal clearances were close to serum clearances in the four studies, but they were lower than endogenous creatinine clearances (Table 1) .
Patients with chronic renal insufficiency.
Moxalactam t1/2e values increased according to the severity of renal failure (Table 2 ) from about (10) . It is highly active against most Enterobacteriaceae, Haemophilus influenzae, Bacteroides fragilis, and Pseudomonas aeruginosa (respective minimal inhibitory concentrations: c0.5 Lg/ml; 0.1 to 3.1 ,ug/ ml; 0.5 to 4 jig/ml; and <12.5 /tg/ml) (1, 2, 5, 7, 10, 15, 16) .
Subjects with normal renal function. In the present study, moxalactam pharmacokinetic parameters were comparable for both the three i.v. doses of 7.5, 15 and 30 mg/kg and the two routes (i.m., i.v.) of administration. After i.v. administration of a single dose of 1 g (@15 mg/ kg) as a bolus injection or as a 20-min infusion, the results were, in some respects, in accordance with the findings of Parsons et al. (14) and Wise et al. (17) . The too low serum levels during a prolonged time, so it should be better to give half the standard dose every 18 to 24 h. In patients undergoing hemodialysis, moxalactam t1/21e was about 20 h not during dialysis, and 50% of the drug was removed by dialysis. The extrarenal purification sessions were usually separated by 48 to 72 h; thus, a dose of 1 g at the end of each hemodialysis session seems to be sufficient to maintain effective serum concentrations between two sessions.
In conclusion, moxalactam elimination halflife is relatively long (=2 h), and the kidney is the major route of elimination. The high serum levels obtained and the reported low serum-protein binding make it possible to maintain effective serum concentrations of moxalactam for a prolonged time, even in cases in which infections are due to bacterial strains with high miniimal inhibitory concentrations. Because of the important increase in elimination half-life in uremic patients, dosage adjustments are necessary and should be adapted to the degree of renal insufficiency. LITERATURE 
